SummarySo far, some prospective metal-based anti-malarial drugs have been developed. The mechanochemical synthesis and characterization of Zn (II) complex with amodiaquine and its anti-malarial efficacy on Plasmodium berghei-infected mice and safety evaluation were described in this study.Solvent-free mechanochemical synthesis and characterization of Zn (II) complex with amodiaquine as well as its anti-malarial efficacy on NK-65 Plasmodium berghei-infected mice and safety were evaluated.Derivatization of amodiaquine with zinc (II) ion enhanced the activity of the drug through significant (p < 0.05) enhancement of parasitemia suppression in established malaria infection in comparison with the controls, while its capacity to clear malaria parasite was similar to that of chloroquine. A significant reduction in the liver, kidney and small intestinal activities of alkaline phosphatase, lactate dehydrogenase and alanine and aspartate aminotransferases was observed, while their levels increased significantly in the plasma. Levels of PCV, Hb, RBC and lymphocytes were significantly reduced (p < 0.05), and significant elevation (p < 0.05) in WBC and neutrophil concentrations across all the treatment groups when compared with control was observed.The result indicates that coordination of zinc (II) to amodiaquine by mechanical induction improved its anti-malarial activity, while the alterations in the investigated biochemical parameters suggest functional and structural toxicity. Thus, Zn (II) complex with amodiaquine may not be completely safe for prolonged and repeated use as an oral anti-malarial remedy.
References
1.
Farombi EO, Olowu BI, Emerole GO. Effect of three structurally related antimalarial drugs on liver microsomal components and lipid peroxidation in rats. Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology. 2000;126(3):217–24.
2.
Huang J, Zhou W, Dong W, Watson AM, Hong Y. Directed, efficient, and versatile modifications of the Drosophila genome by genomic engineering. Proceedings of the National Academy of Sciences. 2009;106(20):8284–9.
3.
Ye XR, Daraio C, Wang C, Talbot JB, Jin S. Room Temperature Solvent-Free Synthesis of Monodisperse Magnetite Nanocrystals. Journal of Nanoscience and Nanotechnology. 2006;6(3):852–6.
4.
Bawa S, Kumar S, Drabu S, Kumar R. Structural modifications of quinoline-based antimalarial agents: Recent developments. Journal of Pharmacy And Bioallied Sciences. 2010;2(2):64.
5.
Sheldon RA. Green solvents for sustainable organic synthesis: state of the art. Green Chemistry. 2005;7(5):267.
6.
Biot C, Dubar F, Khalife J, Slomianny C. Opening up the advantages of the ruthenocenic bioprobes of ferroquine: distribution and localization in Plasmodium falciparum-infected erythrocytes. Metallomics. 2012;4(8):780.
7.
Combes V, Souza JBD, Rénia L, Hunt NH, Grau GE. Cerebral malaria: Which parasite? Which model? Drug Discovery Today: Disease Models. 2005;2(2):141–7.
8.
Reitman S, Frankel S. A Colorimetric Method for the Determination of Serum Glutamic Oxalacetic and Glutamic Pyruvic Transaminases. American Journal of Clinical Pathology. 1957;28(1):56–63.
9.
Wroblewski F, Ladue JS. Lactic Dehydrogenase Activity in Blood. Experimental Biology and Medicine. 1955;90(1):210–3.
10.
Sánchez-Delgado RA, Navarro M, Pérez H, Urbina JA. Toward a Novel Metal-Based Chemotherapy against Tropical Diseases. 2. Synthesis and Antimalarial Activity in Vitro and in Vivo of New Ruthenium− and Rhodium−Chloroquine Complexes. Journal of Medicinal Chemistry. 1996;39(5):1095–9.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
